Skip to main content
. 2020 Oct 2;11:555047. doi: 10.3389/fphar.2020.555047

Figure 2.

Figure 2

Effect of eslicarbazepine acetate on Nav1.5 currents. (A) Representative Na+ currents in an MDA-MB-231 cell elicited by a depolarisation from -120 to -10 mV in physiological saline solution (PSS; black), eslicarbazepine acetate (ESL; 300 μM; red) and after washout (grey). Dotted vertical lines define the time period magnified in (B). (B) Representative persistent Na+ currents in an MDA-MB-231 cell elicited by a depolarisation from -120 to -10 mV. (C) Representative Na+ currents in an MDA-MB-231 cell elicited by a depolarisation from -80 to -10 mV. (D) Normalized Na+ currents in MDA-MB-231 cells elicited by a depolarisation from -120 to -10 mV. (E) Normalized Na+ currents in MDA-MB-231 cells elicited by a depolarisation from -80 to -10 mV. (F) Representative Na+ currents in a HEK-Nav1.5 cell elicited by a depolarisation from -120 to -10 mV in PSS (black), ESL (300 μM; red) and after washout (grey). Dotted vertical lines define the time period magnified in (G). (G) Representative persistent Na+ currents in a HEK-Nav1.5 cell elicited by a depolarisation from -120 to -10 mV. (H) Representative Na+ currents in a HEK-Nav1.5 cell elicited by a depolarisation from -80 to -10 mV. (I) Normalized Na+ currents in HEK-Nav1.5 cells elicited by a depolarisation from -120 to -10 mV. (J) Normalized Na+ currents in HEK-Nav1.5 cells elicited by a depolarisation from -80 to -10 mV. Results are mean + SEM. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; one-way ANOVA with Tukey tests (n = 12–14). NS, not significant.